You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Bayer will offer Veracyte's Afirma Xpression Atlas to identify underlying drivers in tumors of late-stage or metastatic thyroid cancer patients resistant to radioactive iodine therapy.
Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.
Patients with luminal breast cancer subtypes may do just as well without anthracycline-based chemo and avoid unnecessary toxicities, a study showed.
The company plans to present early data this year from its collaboration with Johnson & Johnson to develop a nasal swab-based lung cancer genomic classifier.